Cantor Fitzgerald Issues Negative Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Cantor Fitzgerald lowered their FY2024 earnings estimates for Zevra Therapeutics in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn ($1.97) per share for the year, down from their prior estimate of ($1.61). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.92) per share.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million during the quarter, compared to the consensus estimate of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same quarter in the prior year, the business posted ($0.40) earnings per share.

A number of other research firms have also issued reports on ZVRA. William Blair raised shares of Zevra Therapeutics to a "strong-buy" rating in a research report on Friday, August 30th. Guggenheim started coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a "buy" rating and a $20.00 price target for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research note on Monday, September 30th. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group dropped their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $21.00.

Zevra Therapeutics Stock Performance

ZVRA traded down $0.02 during trading on Monday, reaching $8.60. 695,100 shares of the company's stock were exchanged, compared to its average volume of 549,014. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.21. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.00. The stock has a market capitalization of $452.53 million, a P/E ratio of -4.28 and a beta of 1.93. The company's fifty day simple moving average is $8.03 and its 200-day simple moving average is $6.51.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Sanctuary Advisors LLC acquired a new stake in Zevra Therapeutics in the 2nd quarter valued at $474,000. Jacobs Levy Equity Management Inc. grew its stake in Zevra Therapeutics by 102.4% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company's stock valued at $201,000 after acquiring an additional 17,557 shares during the period. Simplify Asset Management Inc. acquired a new stake in Zevra Therapeutics in the 3rd quarter valued at $833,000. Price T Rowe Associates Inc. MD acquired a new stake in Zevra Therapeutics during the 1st quarter worth $64,000. Finally, Vanguard Group Inc. raised its holdings in shares of Zevra Therapeutics by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company's stock worth $9,883,000 after acquiring an additional 58,866 shares during the period. Institutional investors and hedge funds own 35.03% of the company's stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.